


































Microsoft Word - Cervical cancer and Ethical issues in HPV Vaccination_17Jan


Bangladesh Journal of Bioethics 2017; 8(2):30-37 
 

 

31 

 

Cervical Cancer and Ethical issues in HPV Vaccination 

 

Fariha Haseen1, Sadia Akther Sony2 

 

1. Assistant Professor Department of Public Health and Informatics 

Bangabandhu Sheikh Mujib Medical University. Email: farhaseen3@gmail.com 

 

2.  Research Program Manager 

Department of Public Health and Informatics, Bangabandhu Sheikh Mujib Medical University 

 

Abstract: Human Papilloma Virus (HPV) infection causes death of 270,000 people die from every 

year. Sexually transmitted HPV was found one of the major causes of cervical cancer. World 

Health Organization (WHO). Cervical cancer (CC) is one of the top five cancers that affect women 

around the world. In June 2006, the Food and Drug Administration (FDA) approved a new vaccine 

for women, Gardasil, produced by the pharmaceutical company Merck that protects against 

infection by certain strains of HPV, including the two strains that cause most cases of cervical 

cancer. Vaccinations are counted as one of public health’s important development but there is an 

ethical dilemma between balancing personal autonomy and protection of the entire at risk 

population. The vaccine caused very few side effects like local reactions whereas signs or 

symptoms of greater importance were very. Moreover it was considered that the vaccine is has an 

efficacy of practically 100% in prevention of precancerous lesion caused by the viral genotypes 

included in the vaccine. Bioethicists were not convinced about compulsory vaccination laws as the 

values of patient autonomy and informed consent to be preeminent to them. Not surprisingly, some 

have expressed wariness about or opposition to mandating HPV vaccination. A critical question is 

whether achieving a higher level of coverage justifies the infringement on parental autonomy that 

compulsory vaccination inevitably entails. Recommendation of the universal vaccination of girls 

and young women may evolve ethical challenges which might make it difficult for smooth 

implementation of the vaccination campaigns. Review of the ethical issues in HPV vaccination 

will constitute the main part of our paper. 

Key words: HPV, Cervical cancer, Ethical Issues 

Background: Human papilloma virus (HPV) is common in   human. Among more than 100 

different types of HPV all are not health threatening. Some cause common condylomas and others 

plantar warts, but there is a group of HPVs that mainly infects the mucous epithelium of the 

anogenital tract and has an oncogenic nature1. 

Cervical cancer is the fourth most frequent cancer in women in the world and in 2012 there were  

approximately 530,000 new cases which represented 7.5% of all female cancer deaths and around 

270,000 people die from Human Papilloma Virus (HPV) infection every year2,3.  



Bangladesh Journal of Bioethics 2017; 8(2):30-37 
 

 

32 

 

The incidence is highest in developing countries. The main reasons behind this situation are lack 

of resources in secondary prevention and treatment of the disease and poor sex education of the 

population2,3,4,5. According to World Health Organization (WHO) sexually transmitted Human 

Papilloma Virus (HPV) is one of the major causes of cervical cancer. Two HPV strains (16 and 

18) cause 70% of cervical cancers and precancerous cervical lesions. Cervical cancer (CC) is one 

of the top five cancers that affect women around the world6.  

 

 The pharmaceutical company Merck produces Gardasil, which prevents infection caused by 

certain strains of HPV.  The Food and Drug Administration (FDA) approved a Gardasil as a 

vaccine for women in June 2006. Gardasil prevents two strains (16 and 18) of HPV which cause 

most cases of cervical cancer7. 

 

The HPV vaccine is effective, if it is delivered before exposure to the virus, and preferably, at the 

pre-pubertal stage of a woman’s life because the antibody responses are higher compared to those 

of after puberty8. The lifetime risk of cervical cancer can reduce by 44% among 70% of the pre-

adolescent girls (girls below age 12) who are vaccinated against HPV9. The common side effects 

the vaccine have been mainly local reactions. In rare cases more severe signs or symptoms were 

found10. Moreover it is very important that the vaccine is has a 100% efficient to prevent 

precancerous lesions caused by the viral genotypes included in the vaccine11. 

 

Though an ethical dilemma lies in the balance of personal autonomy and choice and the protection 

of the population from the risk, vaccinations are counted as one of greatest achievements public 

health. From an epidemiological point of view, due to achieve protection against human papilloma 

virus (HPV) infection and potential development of cervical cancer among women. HPV vaccine 

is widely accepted even though it may lead to the neglect of other preventive strategies against 

cervical cancer6. 

 

Policy decisions could be evaluated through several ethical theories. Utilitarianism, natural law 

theory via the Principle of Double Effect, and Principlism are common among the theories which 

are used; brief discussions of Religious Ethics and other possible approaches are added because of 

the criteria of the policy questions. Zikkerman (2006) did a striking analysis that applies ethical 

theories, such as utilitarianism, rule of double effect and principlism are needed for policy 

considerations. It was reported from the analyses that HPV vaccination can be recommended 

universally, including at ages 11–12 years12. Bioethicists, who generally hold the values of patient 

autonomy and informed consent to be dominant, were doubtful about the reinforcement of 

vaccination. Some of them were worried about making HPV vaccination mandatory and some also 

opposed it. Compulsory vaccination encompasses the question, if achieving a higher level of 

coverage justifies the violation on parental autonomy13. 

 



Bangladesh Journal of Bioethics 2017; 8(2):30-37 
 

 

33 

 

Cervical Cancer and Its Prevalence: Among the cancers of women in the world Cervical cancer 

(CC) is found in the top five. International Agency for Research on Cancer (IARC) revealed, in 

2008 there were 530,000 new cases of cervical cancer worldwide, among these cases 85% were in 

developing countries13. Approximately 47, 000 new cases of cervical cancer and 223,000 deaths 

occurred in the year 200015,16. Though the incidence differs in different localities it is the most 

common gynecological cancer in developing countries15,17. In India and Bangladesh 21-23% of 

female cancer is reported to be cervical cancer16,18,19,20. In the developing countries the lack of 

consciousness is one of the most common reason of the death from this fatal cancer. According to 

World Health Organization statistics, incidence of cervical cancer cases in Bangladesh has been 

estimated 167 per 100,000 populations and 6,582 women die in the country from this cancer21,22. 

The development of Cervical Cancer, anogenital cancers, and oropharyngeal cancers are related 

with HPV types 16 and 1823,24. According to WHO Cervical cancer is caused by sexually 

transmitted HPV26. The other risk factors associated with cervical cancer are sexual orientation 

before the age of 16 years, monogamy, history of sexually transmitted diseases (HIV, HSV-2, 

genital wart etc), high parity, black race, smoking, low socio-economic status, lack of hygiene and 

oral contraceptive use27. 

In 2006, the FDA approved the HPV Vaccine Gardasil (against HR HPV types 16 and 18 as well 

as low-risk types 6 and 11) for all females aged 9 through 26. In 2009, the FDA also approved the 

use of this vaccine in males aged 9 through23,25. 

The high income countries have been succeeded to prevent the disease with prophylactic 

immunization and secondary prevention28,29. 

The Human Papilloma Virus (HPV) vaccine has recently been introduced (2016)for the first time 

in Bangladesh by the Ministry of Health and Family Welfare (MOHFW), with support from the 

Global Alliance for Vaccines and Immunizations (GAVI). This new vaccine introduction 

programme will run for two years in Gazipur district and if it is successful, GAVI will provide 

support for national introduction of HPV vaccine30. 

Ethical issues in HPV vaccination: Like any other vaccines in case of HPV vaccine ethical issues 

are important to understand, which is sometimes context specific. It is important to review the 

dynamics of ethics and HPV vaccine. In recent years several countries has introduced HPV vaccine 

in their national program26. A new round of polarizing debates are started up with the steps taken 

to make the vaccine mandatory. Some religious conservatives were worried and they thought that 

the availability of a vaccine against a sexually transmitted disease would threaten abstinence-based 

prevention messages before the vaccine was licensed, this concern created argument for the 

vaccine. Abstinence is one of the approaches to HIV prevention taken by the Physician 

organization. Preventive measures include abstinence-based prevention massages like counseling 

adolescents and their families for being more responsible on sexual decision making including 

abstinence31. Some religious conservatives thought that the availability of the vaccine could affect 

the promotion of these messages.  Some Advocacy groups agreed availability of the vaccine, but 



Bangladesh Journal of Bioethics 2017; 8(2):30-37 
 

 

34 

 

they remain did not agree on making the vaccine mandatory.  Their perspective was this decision 

of the state may lead to force a child to undergo an intervention that may be incompatible with her 

family’s religious values and beliefs13. 

 

The producers of the HPV vaccines were also included in the ethical controversy. The expense is 

huge for the research to introduce a successful product in the market. A balance in safety and 

efficacy is essential for successful programs. Continuous research maintains the chain of new 

usable products. Vigorous monitoring will record the success and failure of these programs 

globally. The reasonable aspects for HPV vaccine recommendation to people are more important 

than the ethical issues with any type of vaccination program32. But we cannot completely avoid 

the ethical issues while recommending HPV vaccine in a national immunization program of any 

country.  

 

Holman compiled the different barriers to the vaccine.  These barriers were stated by physicians 

and parents. Physicians cite financial concerns and parental attitudes and concerns, while most 

parents expressed the desire for more information about the vaccine before they agree to vaccinate 

their children33. Whether the vaccine is advisable or not of the universal vaccination program, it is 

the basic right of the parents to decide about the sex education for their children, so all the 

information regarding the HPV vaccine must be provided to the parents5. If the parents consider 

the vaccine inappropriate for their daughters they must have the right to refuse to vaccinate their 

daughters. The ultimate decision on vaccinate the children should be taken by their parents to 

ensure parental autonomy34,35,36 . 

 

Conclusion: In summary, it can be said from the above discussion that proposing a universal HPV 

vaccination campaign in girls and young women does not entail any particular ethical difficulties, 

providing that the above mentioned premises are taken into account. However as Government of 

Bangladesh has started a two years piloting program of HPV vaccination in 4 sub-districts 

(upazilas) of Gazipur district before scaling up the vaccine in national immunization program, it 

is very important to document the issues and ethical challenges which might raise concerns among 

parents and community and also to develop and examine innovative strategies to reduce the 

dilemma and address the unanswered questions related with ethical issues of HPV vaccination in 

local context.  

 

 

 

  



Bangladesh Journal of Bioethics 2017; 8(2):30-37 
 

 

35 

 

References: 

1. Molijn A, Kleter B, Quint W, van Doorn LJ. Molecular diagnosis of human papillomavirus 

(HPV) infections. Journal of Clinical Virology. 2005 Mar 31;32:43-51.y 

2. Human papilloma virus (HPV) and cervical cancer [Internet]. World Health 

Organization. 2017 [cited 14 December 2017]. Available from: 

http://www.who.int/mediacentre/factsheets/fs380/en/ 

3. Lacey CJ, Lowndes CM, Shah KV. Burden and management of non-cancerous HPV-

related conditions: HPV-6/11 disease. Vaccine. 2006 Aug 21;24:S35-41. 

4. Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang ZF. Cervical cancer as a priority for 

prevention in different world regions: an evaluation using years of life lost. International 

journal of cancer. 2004 Apr 10;109(3):418-24. 

5. Ferlay J. (GLOBOCAN 2002) Cancer incidence, mortality and prevalence worldwide. 

IARC Cancer Base No. 5, version 2.0. http://www-depdb. iarc. fr/globocan/GLOBOframe. 

htm. 2004 Oct. 

6. Navarro-Illana P, Aznar J, Díez-Domingo J. Ethical considerations of universal 

vaccination against human papilloma virus. BMC medical ethics. 2014 Apr 7;15(1):29. 

7. Walter CS. Ethical, Legal, and Economic Considerations Related to the Mandatory 

Administration of the Human Papilloma virus Vaccine. Notre Dame JL Ethics & Pub. 

Pol'y. 2013;27:611. 

8. Ilter E, Celik A, Haliloglu B, Unlugedik E, Midi A, Gunduz T, Ozekici U. Women's 

knowledge of Pap smear test and human papillomavirus: acceptance of HPV vaccination 

to themselves and their daughters in an Islamic society. International Journal of 

Gynecological Cancer. 2010 Aug 1;20(6):1058-62. 

9. Diaz M, Kim JJ, Albero G, De Sanjosé S, Clifford G, Bosch FX, Goldie SJ. Health and 

economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. 

British journal of cancer. 2008 Jul 22;99(2):230-8. 

10. Cortés J, Martinón F, Ferret G, Garcia E, Ramón JM, Garrido R, Miranda P, Dexeus D, 

Gil A, Cisterna R. Vacunasfrente al virus del papilomahumano: actualizacion. Clínica e 

Investigación en Ginecología y Obstetricia. 2010 Apr 30;37(2):63-74. 

11. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang 

GW, Ferris DG, Steben M, Bryan J, Taddeo FJ. Quadrivalent vaccine against human 

papilloma virus to prevent anogenital diseases. New England Journal of Medicine. 2007 

May 10;356(19):1928-43. 

12. Zimmerman RK. Ethical analysis of HPV vaccine policy options. Vaccine. 2006 May 

29;24(22):4812-20. 

13. Colgrove J. The ethics and politics of compulsory HPV vaccination. New England Journal 

of Medicine. 2006 Dec 7;355(23):2389-91. 

14. Blackman E, Thurman N, Halliday D, Butler R, Francis D, Joseph M, Thompson J, Akers 

A, Andraos-Selim C, Bondzi C, Taioli E. Multicenter study of human papilloma virus and 



Bangladesh Journal of Bioethics 2017; 8(2):30-37 
 

 

36 

 

the human papillomavirus vaccine: knowledge and attitudes among people of African 

descent. Infectious diseases in obstetrics and gynecology. 2013 Jul 16;2013. 

15. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. 

European journal of cancer. 2001 Sep 30;37:4-66. 

16. Sultana R, Sultana N. Clinical profile and treatment protocol of invasive carcinoma of 

cervix. Bangladesh Medical Journal Khulna. 2013 Feb 3;45(1-2):11-4. 

17. Kulkarni PV, Jaiswal SS, Rathod SB, Khalique A, Kulkarni RR. Profile of malignancies at 

Medical College, Ambajogai--(15 years retrospective study). Indian journal of cancer. 

1996 Mar;33(1):31-6. 

18. Banerjee AK, Bhattacharya N, Chowdhury MK, Chattopadhyay R, Sengupta J. Incidence 

of malignancy in Bankura (a retrospective study). Journal of the Indian Medical 

association. 1994 Dec;92(12):400-2. 

19. Sharma RG, Ajmera R, Saxena O. Cancer profile in eastern Rajasthan. Indian journal of 

cancer. 1994 Sep;31(3):160-73. 

20. Huq SF. Common cancers in Bangladesh: their trends through last three decades. 

Bangladesh Med J. 1988;17(3):5563. 

21. Papri FS, Khanam Z, Islam F, Hakim MM. Knowledge and Awareness About Risk Factors 

of Cervical Cancer, Its Screening and Vaccination Among the Women Attending 

Chittagong Medical College Hospital. ChattagramMaa-O-Shishu Hospital Medical 

College Journal. 2015 Nov 16;14(2):57-60. 

22. Khatun SF, Homaira R, Khatun S, Sharmin F et al Performance of  VIA(Visual Inspection 

With Acetic Acid)and Colposcopic Biopsy as a Method Of Screening In Detecting 

Preinvasion and Early Cancerous Lesionof the Cervix.Medicine Today.2011;23(1):13-14 

 

23. Carter JR, Ding Z, Rose BR. HPV infection and cervical disease: a review. Australian and 

New Zealand Journal of Obstetrics and Gynaecology. 2011 Apr 1;51(2):103-8. 

24. C.C.R.Ragin,E.Taioli,J.L.Weissfeldetal.,“11q13amplificationstatus and human Papilloma 

virus in relation to p16 expression defines two distinct etiologies of head and neck 

tumours,” British Journal of Cancer ,vol.95,no.10,pp.1432–1438,2006 

25. FDA, “FDA Approves New Indication for Gardasil to PreventGenital Warts 

inMenandBoys,”Bethesda,Md,USA,2009,http://www.fda.gov/NewsEvents/Newsroom/Pr

essAnnouncements/2009/ucm187003.htm. 

26. Human papillomavirus (HPV) and cervical cancer [Internet]. World Health Organization. 

2017[cited 25 September 2017]. Available from: 

http://www.who.int/mediacentre/factsheets/fs380/en/ 

27. Guner H, Taskiran C. Cervical cancer epidemiology and human papilloma virus. Turkish 

J GynecolOncol. 2007;4:11-9. 

28. Demarteau MN, Breuer T, Standaert B. Selecting a mix of prevention strategies against 

cervical cancer for maximum efficiency with an optimization program. 

Pharmacoeconomics. 2012 Apr 1;30(4):337-53. 



Bangladesh Journal of Bioethics 2017; 8(2):30-37 
 

 

37 

 

29. Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57 

countries: low average levels and large inequalities. PLoS Med. 2008 Jun 17;5(6):e132. 

30. HPV vaccine introduced in Bangladesh [Internet]. South-East Asia Regional Office. 2017 

[cited 25 September 2017]. Available from: 

http://www.searo.who.int/bangladesh/HPVvaccinelaunch/en/ 

31. Post SG, Botkin JR. Adolescents and AIDS prevention: The pediatrician's role. Clinical 

pediatrics. 1995 Jan;34(1):41-5. 

32. White MD. Pros, cons, and ethics of HPV vaccine in teens—Why such controversy? 

Translational andrology and urology. 2014 Dec;3(4):429. 

33. Holman DM, Benard V, Roland KB, Watson M, Liddon N, Stokley S. Barriers to human 

papillomavirus vaccination among US adolescents: a systematic review of the literature. 

JAMA pediatrics. 2014 Jan 1;168(1):76-82. 

34. Javitt G, Berkowitz D, Gostin LO: Assessing mandatory HPV vaccination: who should call 

the shots? J Law Med Ethics. 2008, 36:384–395. 

35.  Horn L, Howards C, Waller J, Ferris DG: Opinions of parents about schoolentry mandates 

for the human papillomavirus vaccine. J Low Genit Tract Dis 2010, 14:43–48. 

36. Sussman AL, Helitzer D, Sanders M, Urquieta B, Salvador M, Ndiaye K: HPV and cervical 

cancer prevention counseling with younger adolescents: implications for primary care. Ann 

Fam Med 2007, 5(4):298–304. 

 

Author Declaration: Fariha Haseen conceived the idea, conducted literature review, and 

developed the manuscript. Sadia Akther Sony conducted literature review and contributed in the 

development of the manuscript. 

Conflict of Interest: Author declared n conflict of interest. 


